11.13.26 -- Prioritizing Quality Over Everything

AAV %Full analysis must distinguish full, empty, and partial capsids, with complementary methods selected according to sample characteristics, analytical needs, development stage, and context.

Discover how EPR complements structural maps by resolving flexible regions, detecting hidden conformational states, identifying differences between grid-based and solution conditions, and more.

Learn how one CDMO tripled production, improved audit readiness, and built customer trust by unifying quality systems and embracing a digital-first approach.

Gain insight into how to adapt your environmental monitoring framework to meet the distinct risk-management and regulatory needs of ATMP facility production.

Controlled cysteine conjugation of a bispecific antibody at DAR 6 and a click chemistry dual-payload conjugate at DAR 8 show how a modular approach handles emerging ADC modalities.

As ADCs grow more complex and expand beyond oncology, robust characterization is essential. See how analytical strategies connect structure to function and identify critical quality attributes.

Real-world HPLC workflows show how closed-system solvent handling can address contamination, downtime, and waste across laboratory settings.

Accelerate intact mass analysis of GLP-1 analogues with automated purity calculations, sub-ppm mass accuracy, and impurity detection for consistent results in under one minute per sample.

A new algorithm developed by a real-time viable particle counter determines the viability of a particle based on its measured optical properties, improving the detection of microorganisms.

Aligning visual inspection systems with site standards prevents costly validation failures. Take a look at strategies to de-risk equipment startup.

Integrating quality early in biopharma development reduces risk, speeds commercialization, and ensures compliance through inspection readiness and ongoing analytical oversight.

Disconnected systems can slow development by making data harder to coordinate. Find out how workflow orchestration and structured experimental design can help labs reduce friction.

Ensure the potency and efficacy of your biologic products with a GMP-compliant potency bioassay, offering accurate real-time assessments for GMP release and stability testing.

Observe how early stable CHO expression data reveals manufacturability issues in complex antibodies that transient screening misses, with case studies showing how this changes lead selection.

Preserving data context across bioanalytical workflows improves decision-making, ensures complete traceability, speeds up study review cycles, and prepares datasets for advanced AI.

A fire in a pharmaceutical cleanroom can be contained, but for sterile manufacturers, smoke can turn a localized event into a far wider decontamination, requalification, and production-recovery challenge.

Explore how human-relevant liver models can improve DILI risk assessment and support stronger development decisions while advancing toward regulatory qualification and scalability.

Single-use system risk extends from initial design through installation and use. Delve into how lifecycle-wide controls can strengthen contamination prevention and support regulatory readiness.

Navigate the challenging path from concept to clinical reality by partnering with an experienced CDMO that can provide the regulatory, clinical, and CMC expertise needed to move your therapeutic forward.